| Project/Area Number |
17590630
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
OSAWA Satoshi (2006) Hamamatsu University School of Medicine, Assistant Professor, 医学部附属病院, 助教授 (10397391)
梶村 昌良 (2005) 浜松医科大学, 医学部附属病院, 講師 (40252184)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IKUMA Mutsuhiro Hamamatsu University School of Medicine, Lecturer, 医学部附属病院, 講師 (00275108)
KANAOKA Sigeru Hamamatsu University School of Medicine, Visiting Professor, 分子診断学講座, 寄附講座教員 (00252172)
SUDA Takafumi Hamamatsu University School of Medicine, Assistant Professor (30291397)
大澤 恵 浜松医科大学, 医学部附属病院, 医員 (10397391)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2006: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2005: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | farnesoid X receptor / guggulsterone / bile acid / Barrett's adenocarcinoma / chemoprevention / farnesoid X受容体 / バレット上皮 / バレット腺癌 |
|---|
| Research Abstract |
Gastroesophageal reflux of bile acid is associated with the development of Barrett's epithelium and thereafter adenocarcinoma. Although bile acids are reported to activate farnesoid X recepor that is one of the nuclear hormone receptors, it is unknown whether its signaling is involved in the development of Barrett's adenocarcinoma. In this study, we examined the effects of guggulsterone, a farnesoid X receptor antagonist, on the signaling pathway, especially Cdx2 expression in esophageal epithelial cells in vitro. Treatment with DCA and CDCA for 24 h increased the Cdx2 expression in Barrett's adenocarcinoma cells. Guggulsterone decreased not only basal Cdx2 expression but also DCA-or CDCA-induced Cdx2 expression. Bile acid-activating signaling pathways of farnesoid X receptor may be novel drug targets to prevent the development of Barrett's adenocarcinoma.
|
